RecruitingPhase 2NCT01803542

Stereotactic Radiotherapy (SBRT) of Lung Metastasis

Lung Stereotactic Radiation Therapy for Patients With Non-small Cell Lung Cancer and Other Cancers

Sponsor

University Health Network, Toronto

Enrollment

200 participants

Start Date

Mar 1, 2006

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer Metastasis From Other Cancers

Summary

The purpose of this institutional protocol is to offer SBRT to selected patients in a controlled environment to refine treatment techniques (including dose/fractionation schedules) and standardize follow-up. SBRT has been in clinical use for over a decade in some institutions and the available data suggest that it can be used safely and with good results. This study will see how effective Stereotactic Body Radiation Therapy is for treating tumours in the lung and how often people have side effects. Radiation therapy is usually given once a day, often for a few weeks. In this study, study participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks. Several reports indicate that this therapy might shrink tumours and control the cancer for extended periods of time. Although specialists started to treat patients with SBRT over 10 years ago, it is still used in relatively few cancer centres.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether stereotactic body radiation therapy (SBRT) — a very focused, high-dose form of radiation given in just a few sessions — can effectively treat lung tumors, either primary lung cancer or cancer that has spread to the lungs from elsewhere in the body. **You may be eligible if...** - You have confirmed early-stage non-small cell lung cancer (NSCLC) that has not spread beyond the lungs, OR cancer from another part of the body that has spread to the lungs only - You are considered medically unable to have surgery, or surgery is not your preferred option - You are 18 or older and have a reasonable performance level - You have 3 or fewer lung tumors (if early-stage NSCLC) or 5 or fewer lung tumors (if spread from another site) **You may NOT be eligible if...** - You have an active infection in your lungs or around your heart - You are currently receiving chemotherapy or immunotherapy - You have a history of certain autoimmune diseases (like lupus, rheumatoid arthritis, or scleroderma) - You are a candidate for chemotherapy combined with radiation (chemoradiation) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONStereotactic Radiation

Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.

Locations(1)

Princess Margaret Hospital, University Health Network

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01803542

Related Trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738301 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT0606804925 locations

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386299 locations

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT028388361 location